Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Zacks
Abrir en Zacks
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts forecast that Novartis (NVS) will report quarterly earnings of $2.25 per share in its upcoming release, pointing to no change from the year-ago quarter. It is anticipated that revenues will amount to $14.56 billion, exhibiting an increase of 4.6% compared to the year-ago quarter.

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.

Analysts forecast 'Revenues- Oncology- Tafinlar + Mekinist- Total' to reach $531.43 million. The estimate suggests a change of -3.4% year over year.

The combined assessment of analysts suggests that 'Revenues- Other revenues' will likely reach $527.95 million. The estimate suggests a change of +17.6% year over year.

The average prediction of analysts places 'Revenues- Oncology- Kisqali- Total' at $1.85 billion. The estimate indicates a change of +39.5% from the prior-year quarter.

According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- Total' should come in at $1.78 billion. The estimate suggests a change of +4.9% year over year.

The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tasigna- US' of $24.11 million. The estimate indicates a change of -69.5% from the prior-year quarter.

Based on the collective assessment of analysts, 'Net sales- Oncology- Scemblix- ROW' should arrive at $204.53 million. The estimate indicates a change of +63.6% from the prior-year quarter.

Analysts expect 'Revenues- Oncology- Promacta/Revolade- US' to come in at $31.74 million. The estimate points to a change of -63.9% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Immunology- Cosentyx- US' will reach $1.05 billion. The estimate indicates a year-over-year change of +4%.

The consensus estimate for 'Revenues- Cardiovascular- Entresto- US' stands at $30.58 million. The estimate indicates a year-over-year change of -96.2%.

Analysts predict that the 'Revenues- Oncology- Tafinlar + Mekinist- US' will reach $186.73 million. The estimate indicates a change of -19.5% from the prior-year quarter.

Analysts' assessment points toward 'Net sales- Oncology- Scemblix- US' reaching $391.93 million. The estimate indicates a change of +68.2% from the prior-year quarter.

It is projected by analysts that the 'Net sales- Cardiovascular, renal and metabolic- Leqvio- ROW' will reach $286.98 million. The estimate indicates a change of +77.2% from the prior-year quarter.

View all Key Company Metrics for Novartis here>>>

Novartis shares have witnessed a change of +7.9% in the past month, in contrast to the Zacks S&P 500 composite's no move. With a Zacks Rank #3 (Hold), NVS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Novartis AG (NVS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research